
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India's largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries'.
此公司進入各市場的次序 — 由最舊至最新
註冊以查看完整訊號動態
Alkem Laboratories Ltd. 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
Alkem Laboratories Ltd.你 | 0 | 0 | 0% | 0 | 32 |
Assistant Manager - Admin/Facility Management
查看招聘Mumbai, Maharashtra, India · 3日前
Human Resource Business Partner
查看招聘Mumbai, Maharashtra, India · 上星期
Product Manager - International Business
查看招聘Navi Mumbai, Maharashtra, India · 上星期
無進行中的廣告活動
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
印度製藥市場11月同比增長9.9%,主要由新產品推出和價格上漲推動。大多數療法領域呈現健康增長,皮膚科領先,增長15.8%。
值得關注的股票包括塔塔電力、魯平製藥、RVNL、NLC印度、ICICI保誠人壽和Alkem實驗室。塔塔電力報告利潤增加,魯平製藥澄清了一種通用HIV藥物的FDA批准狀態。
2025年2月7日,包括LIC、NHPC、Ola Electric、Mazagon Dock、Delhivery和M&M在內的230多家公司將公布第三季度財報。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Alkem Laboratories Ltd. 業務、市場及增長訊號的快速解答。
